Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $12.6 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 36.7% year-over-year to $12.6 million in Q1 2026; TTM through Mar 2026 was $12.6 million, a 36.7% decrease from a year earlier, with the FY2025 full-year figure at $19.1 million, up 5.99% from the prior year.
• Other Non-Current Liabilities slipped to $12.6 million in Q1 2026 per ACAD's latest filing, from $19.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $28.5 million in Q2 2025 and bottomed at $200000.0 in Q1 2024.
• The 5-year median for Other Non-Current Liabilities is $12.6 million (2026), against an average of $12.2 million.
• Across the five-year window, Other Non-Current Liabilities plunged 96.23% in 2024 and soared 9881.5% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $9.1 million in 2022, then jumped by 66.93% to $15.1 million in 2023, then climbed by 19.21% to $18.1 million in 2024, then climbed by 5.99% to $19.1 million in 2025, then plunged by 33.97% to $12.6 million in 2026.
• Per Business Quant, the three latest ACAD Other Non-Current Liabilities figures stand at $12.6 million (Q1 2026), $19.1 million (Q4 2025), and $13.9 million (Q3 2025).